PSA density
Divides serum PSA by prostate volume measured on transrectal ultrasound or MRI, helping distinguish benign hyperplasia-related elevation from cancer-related elevation.
Calculate with transparency
Check the population, units and version. The result shows the formula or classification; it does not make an automatic treatment decision.
Preparing the form…
- Check the method
- Enter the data
- Check the result
Method · Limits of application
PSA density/Benson 1992: PSA/volume, ng/mL/cm³; no universal cutoff assumed
Benson 1992 studied PSA density in men, with prostate volume measured by transrectal ultrasound and intermediate PSA of 4.1–10 ng/mL using the Hybritech assay. The article describes risk nomograms; PSA/volume alone is not a diagnosis and does not establish a universal cutoff. The volume method, PSA assay and population of application must be considered.
Conditions of use
Check the population, units, inclusion and exclusion criteria, and version in the original source. A result alone does not establish a diagnosis, discharge decision or prescription.
Documented parameters
- Total PSA · ng/mL
- Prostate volume (transrectal ultrasound or MRI) · mL (cm³)
3/3 reference cases checked. Numerical tests are not clinical validation.
Relationship with cancer research
Specific oncological application
Relates PSA to prostate volume when evaluating suspected prostate cancer. Interpret with the source version and diagnostic context.
Applications: Early detection and risk assessment · Biomarkers